Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

April 07, 2009 09:00 ET

Urodynamix Announces Completion of Commercial Shipment of uroNIRS 2000 to Medical Measurement Systems B.V.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 7, 2009) - Urodynamix Technologies Ltd. ("Urodynamix") (TSX VENTURE:URO) today announced that it has completed its first commercial shipment of uroNIRS 2000 product to Medical Measurement Systems B.V. ("MMS"), a leading developer and distributor of medical diagnostic systems for urology, gastroenterology and neurology headquartered in the Netherlands. The order valued at $175,000US, will be used by MMS to spearhead the introduction of the product in the EU.

"The uroNIRS 2000 was very well received at the EAU in Stockholm and we are delighted to have completed the delivery of our first shipment to our partner MMS." said Barry Allen, President and CEO of Urodynamix Technologies Ltd. "The urology market is very interested in NIRS and we are excited about introducing the user friendly and cost effective device to the global urology office market where we believe our quick non-invasive diagnostic procedure will have incredible value."

Along with their dominant presence in product innovation, development and distribution in the urodynamics markets throughout Europe and Asia, MMS has strong distribution channels in North America. MMS is a key part of Urodynamix's expansion strategy to partner with geographic market leaders and capitalize on significant opportunities globally for uroNIRS technology.

"MMS is excited about introducing the uroNIRS 2000 Bladder Monitor in Europe, North America and beyond." said Arjen J. de Weerd, President of MMS. "We want to provide the latest advances in non-invasive diagnostic technology to our global customer base and the uroNIRS 2000 is one of them."

UroNIRS 2000 is based on a wireless tablet PC with Urodynamix's proprietary sensor configuration and is compact, portable and specifically designed for ease of use in the physician's office setting. The non-invasive procedure is used to confirm the presence of bladder outlet obstruction in men by identifying patients that have healthy bladder function yet suffer from weak urinary stream, hesitancy, urinary retention and related symptoms. UroNIRS 2000 is safer, faster, less expensive and more comfortable than conventional catheter-based diagnostics for the same condition. Clinical studies have shown that UroNIRS has an 86% success rate for accurately identifying obstructed male patients, most of whom are good surgical candidates.

Lower urinary tract symptoms (LUTS) and urinary incontinence (UI) are common in middle-aged men, with the prevalence of LUTS believed to be as high as 90% in men aged 50 to 80 years old. The terms describe a range of urinary symptoms that may be linked with prostate disease or bladder dysfunction. LUTS is most often associated with an enlarged prostate; however symptoms alone cannot be used to make an accurate diagnosis or ensure appropriate treatment of the underlying disease. Expensive, time consuming and painful invasive pressure-flow urodynamic studies currently offer the only way to differentiate between LUTS caused by prostatic obstruction and bladder disease. The uro NIRS technology is a desirable alternative to traditional procedures.

About Medical Measurement Systems B.V.

MMS has been producing urodynamic systems for more than 20 years, including Solar™, Solar SmartFlow™ Urodynamics Systems and Flowmaster™ Uroflowmetry products. MMS has an outstanding reputation for product development and innovation. Their engineers, sales and marketing teams have daily contact with practicing nurses and physicians all over the world, enabling MMS to develop diagnostic systems that exactly meet the needs of today's healthcare professionals.

The main corporate office of MMS is located in Enschede, the Netherlands, where all products are designed and tested to comply with American and European medical safety regulations as well as international quality standards.

Global distribution takes place through branch offices in the United States, Germany and The Netherlands and a worldwide network of highly qualified distributors who sell and service MMS systems to university, public and private hospitals in more than 60 countries.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information